RxDoctor Payments DataLook up a doctor →

Vinod Thourani, MD

Thoracic Surgery (Cardiothoracic Vascular Surgery) · Marietta, GANPI 1851480412

Payments from drug & device makers

$5,633,298in general payments, 2019–2025

Across 1,739 payments — averaging $3239.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3.9M
  • Abbott$1.1M
  • Z-medica, LLC$302K
  • Atricure, Inc.$159K
  • AbbVie$79K
  • Boston Scientific$31K
  • plus $118K from 32 others
$2,800in research payments, 2019–2025

Across 3 payments — averaging $933.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Corcym Inc$3K

What the payments were for

  • Consulting fees$718,25258%
  • Speaking & faculty fees$159,57913%
  • Grants$670%
  • Travel & lodging$81,4177%
  • Food & beverage$46,5984%
  • Education$2680%
  • Ownership interest$223,68218%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,633,298 in reported general payments places this provider in the 95th percentile of 144 thoracic surgery (cardiothoracic vascular surgery) providers in Georgia.

See all thoracic surgery (cardiothoracic vascular surgery) providers in Georgia

Medicare billing

Part B allowed, 2024
$337,973
Medicare patients
464
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$12,647
ClopidogrelClopidogrel Bisulfate77$478
Amiodarone Hcl15$395
Metoprolol Tartrate91$268
Atorvastatin Calcium43$193
Hydralazine Hcl21$151
Mupirocin18$134
Warfarin Sodium33$109
Rosuvastatin Calcium12$68
Tramadol Hcl12$49
Famotidine11$48
Spironolactone11$26
Potassium Chloride12$21
Furosemide24$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$12,64722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 thoracic surgery (cardiothoracic vascular surgery) providers in Georgia.

Other thoracic surgery (cardiothoracic vascular surgery) in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →